IRMD übertreffen die 34 der letzten 39Schätzungen.
87%
Nächster Bericht
Datum des nächsten Berichts
29. Jan. 2026
Estimate forQ4 25(Revenue/ EPS)
$22.03M
/
$0.48
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+3.91%
/
+2.13%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+13.63%
/
+9.09%
iRadimed Corporation earnings per share and revenue
On 03. Nov. 2025, IRMD reported earnings of 0.47 USD per share (EPS) for Q3 25, beating the estimate of 0.46 USD, resulting in a 1.27% surprise. Revenue reached 21.20 million, compared to an expected 20.91 million, with a 1.40% difference. The market reacted with a +9.50% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of 0.48 USD, with revenue projected to reach 22.03 million USD, implying an increase of 2.13% EPS, and increase of 3.91% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
What were iRadimed Corporation's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, iRadimed Corporation reported EPS of $0.47, beating estimates by 1.27%, and revenue of $21.20M, 1.4% above expectations.
How did the market react to iRadimed Corporation's Q3 2025 earnings?
The stock price moved up 9.5%, changed from $76.81 before the earnings release to $84.11 the day after.
When is iRadimed Corporation expected to report next?
The next earning report is scheduled for 29. Jan. 2026.
What are the forecasts for iRadimed Corporation's next earnings report?
Based on 4
analysts, iRadimed Corporation is expected to report EPS of $0.48 and revenue of $22.03M for Q4 2025.